U.K. firm Kontron goes into receivership
U.K. ultrasound and patient monitoring firm Kontron Instruments has gone into receivership, according to the administrator of its accounts, international accounting firm KPMG. KPMG attributed the company's failure to the reduction in healthcare spending
U.K. ultrasound and patient monitoring firm Kontron Instruments has gone into receivership, according to the administrator of its accounts, international accounting firm KPMG. KPMG attributed the company's failure to the reduction in healthcare spending in Europe, 1998's downturn in the Asian market, and increased competition in the overall healthcare market. Watford, U.K.-based Kontron reported revenues of about $24 million for the 12 months ended June 30, 1997.
The company's assets include intellectual property rights to its monitoring products, an electronic assembly plant and its machinery, raw materials, and stock. KPMG seeks to sell Kontron as a going concern and expects to find a buyer shortly, according to Paul Jeffery, administrative receiver for KPMG in Hertfordshire, U.K. Kontron owes roughly $8 million to its 450 creditors.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
Study: Abbreviated Breast MRI Offers Equivalent Accuracy to mpMRI for Women with Dense Breasts
May 20th 2025Emerging research suggests that abbreviated breast MRI offers comparable sensitivity and specificity as multiparametric MRI in women with extremely dense breasts with a nearly 50 percent reduction in reading time for radiologists.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
